How we assess the research behind our guides
A result in a laboratory dish, an experiment in rats and a controlled study in people can all be described as "research", but they tell you very different things.
Orentra separates those evidence types rather than blending them together. Our aim is to show you what has actually been studied, how strong that evidence is, where it came from and what questions are still unanswered.
How we investigate a claim about a peptide
Peptide discussions often begin with a claim: "this heals tendons", "this improves recovery" or "this increases fat loss". We work in the opposite direction.
We first look for the underlying research. Then we ask what was studied, who or what was studied, how the compound was delivered, what outcome was measured and how convincing the result actually was.
The explanation in a guide should reflect that study context, including the details that limit what we can conclude.
Why we distinguish human, animal and laboratory studies
Human research
Research conducted in people. This can range from controlled clinical trials to small pilot studies, which test an idea on a small scale. It also includes observational studies, which follow people without assigning a treatment, and reviews of existing medical records.
We pay attention to study size, controls, randomisation, blinding, route, duration, outcomes and whether the findings have been independently reproduced.
Animal research
Animal studies can show biological effects that are difficult or impossible to study initially in people. They are particularly common in early peptide research.
They can make an idea more plausible, but they cannot by themselves establish that the same result will occur in humans.
Laboratory research
Cell, tissue and biochemical studies can help explain how a peptide may interact with receptors, signalling pathways or repair processes.
These studies are useful for understanding mechanism: the biological process through which a compound might act. They are not direct evidence that a compound produces a meaningful effect in a person.
What Orentra's human-research labels mean
These labels are broad editorial summaries of the human research discussed in a guide. They are not a formal evidence-grading system, a safety score, regulatory approval or a recommendation to use a compound. Evidence can be strong for one use and weak for another, so the full guide matters more than the label alone.
Multiple meaningful human studies, normally including controlled research, with enough evidence to assess particular effects with more confidence than an isolated early study allows. This does not mean every claimed use has been established.
Human research exists and provides useful information, but important limitations or unanswered questions remain.
Human exposure or small human studies exist, but the evidence base is still too limited for confident general conclusions.
Human evidence may consist of isolated reports, very small studies or incomplete published material.
The research assessed for the guide is in cells, tissues or animals, rather than studies establishing effects in people. This describes the evidence we identified at review; it is not proof that no human research exists anywhere.
Orentra has not yet completed its evidence review for that compound. We deliberately leave the label unresolved rather than guess.
Which sources we use and what each can tell us
Whenever possible, Orentra works from primary sources rather than repeating claims from peptide sellers, social-media posts or other summary websites.
Original clinical, animal and laboratory studies. Peer review means other specialists have assessed a paper before publication; it does not guarantee that its conclusions are correct.
Official information from bodies such as the US Food and Drug Administration (FDA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Approval statements need to identify the country, product and use concerned.
Registries describe planned studies and their status. A protocol sets out how a study will be conducted. Registration alone does not mean a trial succeeded or that results are available.
Reviews that use a defined method to find and assess studies. These help us understand the wider evidence and find original papers; their usefulness still depends on the studies included.
The World Anti-Doping Agency (WADA) and other official anti-doping sources where competition rules are relevant.
Pharmaceutical and analytical sources where peptide chemistry, purity or formulation matters.
How we handle announcements and incomplete results
Company announcements and conference summaries can provide early information, but may leave out methods or results needed to assess a study fully. We identify them as such rather than presenting them as published, peer-reviewed papers. A preprint is a paper shared before peer review and needs the same clear distinction.
Where funding or authors' commercial interests are reported, they are relevant context. Company funding does not automatically invalidate a finding, and publication does not make a study independent of its sponsor. We look at the methods, reporting and whether other research supports the result.
We show what researchers actually did
Where human research exists, Orentra may show the amount studied, route of administration, study duration and the population involved.
These are published research protocols. They describe what happened in a particular study. They should not be read as personalised dosing recommendations or as evidence that the same protocol applies to a different purpose, route or person.
Showing the original study context is more useful than repeating a single number without explaining where it came from.
What we look for when reading a study
A result in two people carries different weight from a large controlled trial.
Without one, it can be much harder to know whether the compound caused the result.
Randomisation assigns participants to groups by chance. Blinding keeps participants, researchers or assessors unaware of the assignment. Both can reduce bias, although neither removes every possible source of error.
A biomarker is a measured sign of a biological process, such as a blood-test result. A change in a biomarker does not necessarily mean people feel better, avoid illness or live longer. We distinguish these outcomes rather than treating them as interchangeable.
A substance taken by mouth, delivered into a vein or delivered into a joint may reach different tissues in different amounts. Findings from one route cannot simply be transferred to another.
Independent replication increases confidence that a finding is not unique to one study.
How we weigh benefits, harms and missing information
We consider the size of an effect as well as whether a study reports a positive result. Group averages can hide substantial differences between participants. The number who stopped taking part, the reasons they stopped and how missing results were handled can also change the interpretation.
Safety findings depend on how many people were studied, for how long and which problems researchers looked for. A small or short study may miss rare or delayed harms. An absence of reported harm is therefore not enough to establish safety.
How we describe findings that are uncertain or conflicting
If evidence is weak, mixed or missing, we say so. If most of the research is in animals, we do not describe it as though it has already been demonstrated in people.
We also do not give a compound an evidence rating simply because it is popular. Search volume, online enthusiasm and scientific evidence are separate things.
At the same time, limited human evidence does not mean that the underlying preclinical research should be ignored. Orentra's job is to show you both sides of that distinction.
How review dates and new findings affect a guide
Each live peptide guide records the period through which its research has been reviewed. Orentra also monitors for new papers, clinical developments, regulatory changes and relevant safety information.
New research does not automatically change a page. It is first reviewed to determine whether it materially changes the evidence, adds useful context or affects an existing statement.
A review date shows the point through which the evidence was assessed; it is not a guarantee that every subsequent development has already been added. New-paper alerts help identify material to review, but an alert itself is not a verified update. When a source reveals an error, the affected statement and its supporting references need to be checked and corrected.
Find a guide and explore its sources
You can put these explanations into context by browsing the peptide guides or the technical guides. If you are new to the subject, start with our introduction to peptides. Each guide's source links let you follow the research discussed.